Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 14.67
-0.11 (-0.74%)
Feb 13, 2026, 3:00 PM CST
SHA:600535 Revenue
In the year 2025, Tasly Pharmaceutical Group had annual revenue of 8.24B CNY, down -3.08%. Tasly Pharmaceutical Group had revenue of 1.93B in the quarter ending December 31, 2025, a decrease of -5.39%.
Revenue
8.24B
Revenue Growth
-3.08%
P/S Ratio
2.66
Revenue / Employee
751.64K
Employees
10,958
Market Cap
21.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.24B | -261.66M | -3.08% |
| Dec 31, 2024 | 8.50B | -175.87M | -2.03% |
| Dec 31, 2023 | 8.67B | 36.58M | 0.42% |
| Dec 31, 2022 | 8.64B | 685.47M | 8.62% |
| Dec 31, 2021 | 7.95B | -5.62B | -41.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 15.20B |
| Apeloa Pharmaceutical Co.,Ltd | 10.50B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.02B |
| Betta Pharmaceuticals | 3.26B |
| Walvax Biotechnology | 2.40B |
| Jilin Aodong Pharmaceutical Group | 2.34B |